Erudio Bio
Erudio powers AI drug discovery with ground-truth binding data.
Our Versatile Smart Assay (VSA) converts molecular interactions into kinetics-resolved “stickiness” labels (force curves, on/off characteristics) at scale. These labels train and validate AI models so they rank true binders and filter look-alikes early.
With bioTCAD, our data + software layer, teams cut wet-lab cycles and de-risk candidates before expensive assays.
(Multiplex is how we scale: VSA reads 50–100 interactions from ~10 µL in a single run.)
Our Technology
Our innovative patented technology addresses critical limitations in current multiplexed assay methods, and provides comprehensive binding data that opens new possibilities in disease detection and drug development.
Powering AI drug discovery
Erudio provides the missing ingredient for AI-powered drug discovery: ground-truth binding labels that include strength and kinetics. Our datasets let models separate true binders from look-alikes and activity cliffs, improving hit ranking, calibration, and go/no-go decisions.
Comprehensive Data with Force Spectroscopy
Our patented dynamic force spectroscopy reads the energy needed to pull molecules apart, revealing on/off rates, unbinding forces, and specificity. By measuring kinetics—not just presence—we filter out cross-reactivity and non-specific binding, allowing us to perform accurate and comprehensive multiplexed assays despite cross-reactivity and non-specific bindings.
Scalable Data Generation
VSA reads 50–100 interactions per run from ~10 µL samples, enabling rapid build-out of task-specific panels (cytokines, antibodies, glycans). That scale turns force curves into production-grade datasets—fuel for both discovery and validation.
Our Team
Meet the Team
Meet the brilliant minds driving innovation at Erudio Bio, Inc. Our diverse team of scientists, researchers, and visionaries is dedicated to revolutionizing the biotech industry.
CEO / CTO
Kee-Hyun Paik
Kee-Hyun Paik is the President and co-Founder of Erudio Bio, Inc. a pioneering biotech company in the San Francisco Bay Area. With over two decades of experience in biotechnology, Kee-Hyun's background includes co-founding Multerra Bio, Inc., postdoctoral research at Stanford University School of Medicine, and sr. engineering roles at Samsung Electronics and ISE Inc. He holds a Ph.D. and M.S. in Electrical and Electronics Engineering from Stanford University and a B.S. from Duke University.
COO / Head of Business
Leon Chen
Leon Chen is the co-founder and leads business development and operations at Erudio Bio, Inc., bringing a blend of technical expertise and business acumen to the role. His background includes serving as Director of Product Management at Resilience and holding various leadership positions during a 13-year tenure at Bank of America. Leon holds an MBA in Finance from the USC Marshall School of Business and a BS in Computer Science from Stanford University.
Head of AI
Sunghee Yun
Sunghee Yun is the Co-founder and AI Technology & Product Strategy Lead at Erudio Bio, Inc. He has extensive expertise in AI and Convex Optimization, co-founding Gauss Labs and serving as CTO and Chief Applied Scientist. Sunghee has also held leadership roles at SK hynix and led AI projects at Amazon that generated over $200 million in sales. He holds a Ph.D. in Electrical Engineering from Stanford University and is an Adjunct Professor at Sogang University and an Advisory Professor at DGIST.
Advisory Board
Ronald W. Davis
Prof. Biochemistry and Genetics, Director Stanford Genome Tech Center
$15B+ exits
William J. Greenleaf
Prof. Genetics and Applied Physics, Stanford University
Karyn Eliot
Retired CIA Sr. Executive
Michael Cola
CEO AEVI Genomic Medicine, President of Shire plc. ($62B sale to Takeda)
Tim Germann
CCO Chief Commercial Officer Carterra Bio
Michael P. Snyder
Professor and Chair of Genetics, Stanford University · Co-founder of Personalis and January AI